Compound: ramipril
SMILES: O=C(O)[C@H]1N(C(=O)[C@@H](N[C@H](C(=O)OCC)CCc2ccccc2)C)[C@H]3CCC[C@H]3C1
InChIKey: HDACQVRGBOVJII-JBDAPHQKSA-N
Synonyms: ramipril, 87333-19-5, Tritace, Altace, Triatec, Ramace, Vesdil, Delix, Cardace, Acovil, Pramace, Hoe-498, Ramiprilum, Unipril, Ramiprilum [Latin], HOE 498, Corpril, Ramipres, Ecator, Hopace, HOE498, DTXSID8023551, L35JN3I7SJ, NSC-758933, C09AA05, CHEBI:8774, DTXCID203551, (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester, (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure, Ramiprilum (Latin), (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydrocyclopenta[b]pyrrole-2-carboxylic acid, (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, Cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-, Zabien, CYCLOPENTA(B)PYRROLE-2-CARBOXYLIC ACID, 1-((2S)-2-(((1S)-1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-, (2S,3AS,6AS)-, Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,6aS)-, Lopace, Ranace, (2S,3aS,6aS)-1-((2S)-2-(((2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta(d)pyrrole-2-carboxylic acid, (2S,3aS,6aS)-1-((2S)-2-(((2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-octahydrocyclopenta(b)pyrrole-2-carboxylic acid, (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[d]pyrrole-2-carboxylic acid, (2S,3aS,6aS)-1-[(S)-N-[(S)-1-Carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid, 1-ethyl ester, RefChem:56358, 642-904-3, Carasel, Quark, Altace (TN), MFCD00865775, Lostapres, Hytren, (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid, CHEMBL1168, (2S,3aS,6aS)-1-((S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid, C23H32N2O5, (2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid, Ramipro, Naprix, (2S,3AS,6AS)-1((S)-N-((S)-1-CARBOXY-3-PHENYLPROPYL)ALANYL)OCTAHYDROCYCLOPENTA(B)PYRROLE-2-CARBOXYLIC ACID 1-ETHYL ESTER, (2S,3As,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]azaniumyl]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylate, Ramipril (Altace), Ramipril (1.0 mg/mL in Methanol), (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name), SMR000466386, Ramipril (USP/INN), SR-05000001908, UNII-L35JN3I7SJ, Pramace;, Triatec;, Tritace;, Unipril;, Acovil;, Altace;, Hypren;, Ramace;, Ramipril CRS, Delix;, Quark;, Ramipril [USAN:USP:INN:BAN], NCGC00016955-01, CAS-87333-19-5, Ramipril (Standard), VOSTALLY, Spectrum_001958, RAMIPRIL [USAN], RAMIPRIL [INN], RAMIPRIL [JAN], RAMIPRIL [MI], RAMIPRIL [VANDF], Spectrum3_001794, Spectrum4_001269, Spectrum5_001721, RAMIPRIL [MART.], RAMIPRIL [USP-RS], RAMIPRIL [WHO-DD], SCHEMBL16059, BSPBio_003347, KBioGR_001858, KBioSS_002512, RAMIPRIL, (+)-, MLS000759523, MLS001216547, MLS001423965, N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid, Ramipril - Bio-X trade mark, BIDD:GT0803, SPECTRUM1505214, RAMIPRIL [ORANGE BOOK], GTPL6339, orb1307911, orb3141285, RAMIPRIL [EP MONOGRAPH], Ramipril, >=98% (HPLC), RAMIPRIL [USP MONOGRAPH], HSDB 8393, HY-B0279R, KBio2_002504, KBio2_005072, KBio2_007640, KBio3_002849, NPD2431, Ramipril (1 mg/mL in Methanol), HMS2051E04, HMS2090L11, HMS2093M10, HMS2231M05, HMS3259J07, HMS3715M16, Pharmakon1600-01505214, ALBB-038665, CYCLOPENTA(B)PYRROLE-2-CARBOXYLIC ACID, 1-(2-((1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-, (2S-(1(R*(R*)),2.ALPHA.,3A.BETA.,6A.BETA.))-, HY-B0279, MSK11236, Tox21_110708, BBL033964, BDBM50084681, EBC-02055, NSC758933, s1793, STK801937, AKOS005622534, Tox21_110708_1, AC-1347, CCG-100833, DB00178, FC27676, KS-1103, NC00083, NC00627, NSC 758933, NCGC00178127-01, NCGC00178127-02, (2S,3aS,6aS)-1-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid, (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid, (2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-cyclopenta[b]pyrrole-2-carboxylic acid, (2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid, (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid, BR164319, SY031735, SBI-0206728.P001, NS00004700, R0219, D00421, EN300-118695, AB00698339-07, AB00698339-08, AB00698339_09, AB00698339_10, Q412666, SR-05000001908-1, SR-05000001908-2, BRD-K89348303-001-14-7, Ramipril, British Pharmacopoeia (BP) Reference Standard, Ramipril, European Pharmacopoeia (EP) Reference Standard, Z1515381509, Ramipril, United States Pharmacopeia (USP) Reference Standard, Ramipril, Pharmaceutical Secondary Standard; Certified Reference Material, (2S,3AS,6AS)-1-((S)-2-((S)-1-ETHOXY-1-OXO-4-PHENYLBUTAN-2-YLAMINO)PROPANOYL)-OCTAHYDROCYCLOPENTA[B]PYRROLE-2-CARBOXYLICACID, (2S,3aS,6aS)-1-[(S)-2-[[(S)-1-Ethoxy-1-oxo-4-phenyl-2-butyl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic Acid, (2S,3aS,6aS)-1-{N-[(2S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl}octahydrocyclopenta[b]pyrrole-2-carboxylic acid, 1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]pyrrole-2-carboxylic acid(Ramipril), 1-[2-(1-ethoxycarbonyl-3-phenylpropylamino)propionyl]octahydrocyclopenta[b]- pyrrole-2-carboxylic acid, 1028843-43-7
Theoretical properties:
molecular_formula: C23H32N2O5
molecular_weight: 416.5 g/mol
exact_mass: 416.23112213 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 6
rotatable_bond_count: 10
heavy_atom_count: 30
topological_polar_surface_area: 95.9 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Felty needles from ether
color: Felty needles from ether
solubility: 3.5mg/L
Descriptions:
{"pubchem": "Ramipril is a dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor, a prodrug, a matrix metalloproteinase inhibitor, a cardioprotective agent and a bradykinin receptor B2 agonist. It is an ethyl ester, a dicarboxylic acid monoester, an azabicycloalkane, a cyclopentapyrrole and a dipeptide. It is a conjugate acid of a ramipril(1-).", "chebi": "A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.", "chembl": "RAMIPRIL is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Ramipril, sold under the brand name Altace among others, is an ACE inhibitor type medication used to treat high blood pressure, heart failure, and diabetic kidney disease. It can also be used as a preventative medication in patients over 55 years old to reduce the risk of having a heart attack, stroke or cardiovascular death in patients shown to be at high risk, such as some diabetics and patients with vascular disease. It is a reasonable initial treatment for high blood pressure. It is taken by mouth.\nCommon side effects include headaches, dizziness, fatigue, and cough. Serious side effects may include liver problems, angioedema, kidney problems, and high blood potassium. Use in pregnancy and breastfeeding is not recommended. It is an ACE inhibitor and works by decreasing renin-angiotensin-aldosterone system activity.\nRamipril was patented in 1981 and approved for medical use in 1989. It is available as a generic medication. In 2023, it was the 211th most commonly prescribed medication in the United States, with more than 2 million prescriptions."}